
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded troche containing atomoxetine hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing atomoxetine are listed in capsule and solution forms. No finished atomoxetine product of any kind is listed in troche form.
Bases for this dose form differ, and the base used decides how USP <795> classifies the preparation for beyond-use dating. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Atomoxetine is a non-stimulant selective norepinephrine reuptake inhibitor that compounding pharmacies prepare as oral capsules and oral liquids by prescription.
Atomoxetine is a non-stimulant medicine for attention-deficit/hyperactivity disorder (ADHD). It blocks the presynaptic norepinephrine transporter, raising norepinephrine levels in the brain, and also raises dopamine in the prefrontal cortex. The exact way it improves ADHD symptoms is not known. Strattera capsules (Eli Lilly) and Atoncy oral solution (Validus) are FDA-approved for the treatment of ADHD in adults and in children 6 years of age and older, and generic capsules and oral solution are also manufactured. The label says the capsules must be swallowed whole and not opened, because atomoxetine irritates the eyes. A prescriber may order atomoxetine compounded when a patient needs a strength, flavor or dye-free vehicle the manufactured products do not offer. Compounded preparations are not FDA-approved and require a prescription.
Atomoxetine carries an FDA boxed warning: it increased the risk of suicidal thoughts in children and teens with ADHD in short-term studies, so watch closely for suicidal thoughts, worsening mood or unusual behavior, especially early and after dose changes. The label also warns of severe liver injury, serious heart problems, raised blood pressure and heart rate, new psychotic or manic symptoms, aggression, trouble urinating, priapism and slowed growth in children. Do not use it with or within 14 days of an MAO inhibitor, or if you have narrow-angle glaucoma, pheochromocytoma or a serious heart or blood vessel condition. Strong CYP2D6 inhibitors such as fluoxetine and paroxetine raise atomoxetine levels, and albuterol and blood pressure medicines need monitoring. Pregnancy data are insufficient to establish risk. The Strattera label reports no human milk data, but LactMed describes very low milk levels in a small study and advises watching a nursing infant for excess sedation. For side effects, talk to your prescriber or pharmacist.
Atomoxetine is a selective presynaptic norepinephrine reuptake inhibitor; the R(-) isomer is the more potent enantiomer, and it also increases prefrontal dopamine. It is metabolized mainly by CYP2D6 to 4-hydroxyatomoxetine. Per the Strattera label, absolute bioavailability is 63 percent in extensive metabolizers and 94 percent in CYP2D6 poor metabolizers, protein binding is 98 percent, and half-life is about 5.2 hours, rising to 21.6 hours in poor metabolizers; exposure doubles in moderate and quadruples in severe hepatic impairment. Labeled indication: ADHD in adults and children 6 years and older (Strattera capsules, Atoncy oral solution). StatPearls lists off-label use in neurogenic orthostatic hypotension. Dosing and titration are per prescriber; the label advises longer titration intervals with strong CYP2D6 inhibitors or in poor metabolizers and notes genetic testing may be considered. Monitor blood pressure and heart rate at baseline, after dose increases and periodically, plus growth in children, liver injury symptoms, mood, suicidality and emergent mania. Atomoxetine is not a controlled substance, and StatPearls notes a lack of abuse potential in clinical studies.
Wash and dry your hands. Place the troche between your cheek and gum or under your tongue, as your label directs, and let it dissolve. Do not chew or swallow it whole unless told to. Dissolving can take up to 30 minutes. Follow your label about eating or drinking around the dose.
Troches are nonaqueous, so a USP <795> default beyond-use date of up to 180 days usually applies. Store in the closed container in a cool, dry place at room temperature, away from heat so they do not soften, and out of reach of children. Discard after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Place 1 troche between cheek and gum and let slowly dissolve